Glyco@Seminar: Francesco Peri

on the November 14, 2019

3:30 pm
Francesco Peri from University of Milan (Italy) will give a talk about “Small molecules targeting Toll-Like Receptors: towards a new generation of therapeutics”.

Full Professor of Organic and Medicinal Chemistry at the Department of Biotechnology and Biosciences, University of Milano-Bicocca.
Permanent professorship at the Ecole Normale Supérieure (ENS) of Lyon (France) where he teaches a course of Medicinal Chemistry (Master level). In 2012, professorship in Organic Chemistry at the University Paris 5, and in 2012 he was Visiting Professor at the Department of Chemistry, University of California, Davis (USA).

Bibliometrics: 105 publications in international journals,    3151 citations, H-index= 33, (21 since 2014), i10-index= 71.
2015-2018, coordination of the H2020-funded MSCA-ETN project TOLLerant (“Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach”, GA number 642157).

The research interests of Peri’s group ( span the disciplines of organic, bioorganic and medicinal chemistry with an emphasis of study of the interactions between small molecules and their biological (pharmacological) targets. In last ten years, innovative hit and lead compounds for drug discovery were projected and synthesized. These molecules were also used as “chemical genetics” tools to study, in collaboration with biologists and immunologists, some important signal pathways in humans.
The research activity of the lab focused in last year in the design, synthesis and biological characterization of small molecules (mainly cationic and anionic glycolipids) able to modulate the activity of the Toll Like Receptor 4 (TLR4) in the perspective to develop new generations of TLR-directed therapeutics. F. Peri did several activities for the technology transfer of the University of Milano-Bicocca, he is administrator of the Foundation U4i (University for Innovation) for the valorization of Research and Technology Transfer of the University of Milano-Bicocca, and he created his spin-off (C2P2 srl).

Active research projects:
1) Synthesis and biological characterization of new molecules active on TLR4 signaling.
2) Pre-clinical development of new anti-inflammatory compounds targeting TLRs, including compounds targeting inflammatory IBDs, neuro-inflammations, Amyotrophic Lateral Sclerosis (ALS) and Rheumatoid Arthritis.(RA)
3) Pre-clinical development of vaccine adjuvants based on TLR4 agonists.
4) New leads for cardiac drugs based on steroid structures (in collaboration with CVie Therapeutics (Taiwan).

Published on November 12, 2019

Practical informations


Nanobio building
570 rue de la Chimie
Campus universitaire de Grenoble